Understanding a stock's ownership structure and analyst forecasts can reveal investment opportunities. Marinus Pharmaceuticals, Inc. is primarily institution-owned, with hedge funds owning 23%. Top shareholders like Tang Capital Management and Sofinnova Investment hold significant stakes.